Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer

OBJECTIVE: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and PI3K/AKT pathways. Effective targeted therapies are urgently needed. We investigated whether rigosertib, a benzyl styryl sulfone RAS sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xinyi, Xiao, Qian, Fu, Dongliang, Zhang, Haochen, Tang, Yang, He, Jinjie, Hu, Yeting, Kong, Xiangxing, Teng, Fei, Liu, Xiangrui, Yuan, Ying, Ding, Kefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832955/
https://www.ncbi.nlm.nih.gov/pubmed/34347396
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832955/
https://www.ncbi.nlm.nih.gov/pubmed/34347396
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0532

Ejemplares similares